Aduro BioTech Inc (NASDAQ:ADRO) COO Gregory W. Schafer sold 40,000 shares of the stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $12.17, for a total value of $486,800.00. Following the completion of the sale, the chief operating officer now owns 133,879 shares of the company’s stock, valued at $1,629,307.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Aduro BioTech Inc (NASDAQ:ADRO) traded down 1.22% on Wednesday, hitting $12.15. The company had a trading volume of 354,202 shares. Aduro BioTech Inc has a one year low of $8.75 and a one year high of $16.43. The stock’s 50-day moving average price is $12.14 and its 200 day moving average price is $10.93. The company’s market capitalization is $895.16 million.

Aduro BioTech (NASDAQ:ADRO) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.02. Aduro BioTech had a negative net margin of 327.87% and a negative return on equity of 31.97%. The firm had revenue of $5.90 million during the quarter, compared to the consensus estimate of $3.98 million. During the same period in the previous year, the firm earned $0.03 earnings per share. The business’s quarterly revenue was down 84.9% on a year-over-year basis. On average, analysts expect that Aduro BioTech Inc will post ($1.37) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/aduro-biotech-inc-adro-coo-gregory-w-schafer-sells-40000-shares/1466648.html.

Several equities research analysts have issued reports on the company. BidaskClub downgraded Aduro BioTech from a “hold” rating to a “sell” rating in a report on Tuesday. Canaccord Genuity set a $30.00 price target on Aduro BioTech and gave the stock a “buy” rating in a report on Thursday, August 3rd. HC Wainwright set a $18.00 price objective on Aduro BioTech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Zacks Investment Research downgraded Aduro BioTech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, Cowen and Company started coverage on Aduro BioTech in a report on Tuesday, July 18th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $19.00.

Hedge funds have recently modified their holdings of the stock. Legal & General Group Plc raised its stake in shares of Aduro BioTech by 11.2% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after buying an additional 1,043 shares during the last quarter. Quantitative Systematic Strategies LLC bought a new stake in shares of Aduro BioTech during the first quarter worth approximately $145,000. Daiwa SB Investments Ltd. bought a new stake in shares of Aduro BioTech during the first quarter worth approximately $153,000. Creative Planning raised its stake in shares of Aduro BioTech by 73.9% in the first quarter. Creative Planning now owns 15,000 shares of the biotechnology company’s stock worth $161,000 after buying an additional 6,375 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in shares of Aduro BioTech by 15.9% in the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after buying an additional 2,119 shares in the last quarter. 35.60% of the stock is owned by institutional investors and hedge funds.

About Aduro BioTech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.